Orphan Europe, part of the Recordati Group, is a pharmaceutical company that develops and distributes orphan drugs for the treatment of rare diseases. Whether you are a physician seeking help and support in your fight to treat a rare disease, a patient looking for information or a company looking for a partnership – Orphan Europe is waiting to hear from you.

Feature story


	Registration of Normosang in Russia The 14/11/2011 at 17:53:26 Orphan Europe is pleased to announce that Normosang (human hemin) has received market approval, in Russia for the treatment of acute attacks of hepatic porphyria (acute intermittent porphyria, hereditary coproporphyria and variegate porphyria. Download here Read the news >>


	8th Middle East Metabolic Group Meeting Events The 21/10/2011 at 17:33:48 October, 27th-29th, 2011 Le Royal Hotel Lebanon Download Programme here Read the news >>


	Rare Disease Day 2012 News The 27/01/2012 at 16:34:02 Rare Disease Day is an annual, awareness-raising event co-ordinated by EURORDIS at the international level and the National Alliances of Patient Organisations at the national level. Read the news >>

Orphan Europe provides treatment for patients suffering from rare diseases all over the world. Read more about the different diseases here.

Orphan Europe has been developing and distributing orphan drugs since 1990 and has today an extensive product portfolio. Read more about some of the orphan medicinal products provided by Orphan Europe.

Provides high-quality, innovative science education for healthcare personnel involved in the diagnosis and management of patients affected by rare diseases.

| Design by Cyim 2007

Feature story

Registration of Normosang in Russia

8th Middle East Metabolic Group Meeting

Rare Disease Day 2012